mergers & acquisitions
Merck KGaA Buying SpringWorks Therapeutics to Strengthen US Presence in Rare Tumors
SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.
Bluebird Bio Backs Take-Private Deal With Carlyle, SK Capital Citing Financing Gaps in Ayrmid's Bid
Ayrmid has not obtained the necessary financing to support its unsolicited, nonbinding written proposal to purchase the company, Bluebird said.
Adaptin Bio Goes Public Through Reverse Merger, Completes $7.7M Private Placement
The firm will use the proceeds to advance its bispecific T-cell engager candidate APTN-101 in glioblastoma.
InformedDNA Acquires Coriell Life Sciences, Adds PGx Capabilities
The companies have begun integrating Coriell's PGx services into InformedDNA's DNAimpact precision health platform for payors and employers.
AstraZeneca to Acquire Cell Therapy Firm EsoBiotec for up to $1B
EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.
Jan 13, 2025
GSK to Acquire IDRx in $1.15B Deal
Nov 22, 2024
Novartis Acquires Kate Therapeutics in $1.1B Deal
Oct 28, 2024
AbbVie to Buy Aliada Therapeutics for $1.4B in Cash
Feb 6, 2024